Integrilin(eptifibatide)
Integrilin (eptifibatide) is a protein pharmaceutical. Eptifibatide was first approved as Integrilin on 1998-05-18. It is used to treat coronary disease, myocardial infarction, and unstable angina in the USA. It has been approved in Europe to treat myocardial infarction and unstable angina.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Eptifibatide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| INTEGRILIN | Merck Sharp & Dohme | N-020718 DISCN | 1998-05-18 | 2 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| eptifibatide | ANDA | 2021-03-22 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| coronary disease | — | D003327 | — |
| myocardial infarction | EFO_0000612 | D009203 | I21 |
| unstable angina | EFO_1000985 | D000789 | I20.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| G9531 | Patient has documentation of ventricular shunt, brain tumor, multisystem trauma, or is currently taking an antiplatelet medication including: abciximab, anagrelide, cangrelor, cilostazol, clopidogrel, dipyridamole, eptifibatide, prasugrel, ticlopidine, ticagrelor, tirofiban, or vorapaxar |
| J1327 | Injection, eptifibatide, 5 mg |
Clinical
Clinical Trials
26 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | 1 | 2 | 1 | — | 4 |
| Coronary artery disease | D003324 | I25.1 | — | — | — | 3 | — | 3 | |
| Non-st elevated myocardial infarction | D000072658 | — | — | — | 1 | — | 1 | ||
| Angioplasty | D017130 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acute coronary syndrome | D054058 | EFO_0005672 | — | 3 | 2 | — | — | 5 | |
| Ischemic stroke | D000083242 | — | 2 | 2 | — | — | 4 | ||
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | 1 | — | — | 1 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stroke | D020521 | EFO_0000712 | I63.9 | 1 | 3 | — | — | — | 3 |
| Unstable angina | D000789 | EFO_1000985 | I20.0 | — | 2 | — | — | — | 2 |
| Brain infarction | D020520 | EFO_0004277 | I63 | — | 2 | — | — | — | 2 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | 1 | — | — | — | 1 |
| Coronary disease | D003327 | — | 1 | — | — | — | 1 | ||
| Septic shock | D012772 | A48.3 | — | 1 | — | — | — | 1 | |
| Inferior wall myocardial infarction | D056989 | EFO_1000983 | — | 1 | — | — | — | 1 | |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 1 | 1 | — | — | — | 1 |
| St elevation myocardial infarction | D000072657 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | EPTIFIBATIDE |
| INN | eptifibatide |
| Description | Eptifibatide is a synthetic homodetic cyclic peptide comprising N(alpha)-(3-sulfanylpropanoyl)homoarginyl, glycyl, aspartyl, tryptophyl, prolyl and cysteinamide residues connected in sequence and cyclised via a disulfide bond. Derived from a protein found in the venom of the southeastern pygmy rattlesnake, Sistrurus miliarus barbouri, eptifibatide is an anti-coagulant that inhibits platelet aggregation by selectively blocking the platelet glycoprotein IIb/IIIa receptor, so preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands. It is used in the management of unstable angina and in patients undergoing coronary angioplasty and stenting procedures. It has a role as a platelet aggregation inhibitor and an anticoagulant. It is an organic disulfide, a macrocycle and a homodetic cyclic peptide. |
| Classification | Protein |
| Drug class | peptides: platelet aggregation inhibitor (GPIIb/IIIa receptor antagonist) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | N=C(N)NCCCC[C@@H]1NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CC(=O)O)NC(=O)CNC1=O |
Identifiers
| PDB | — |
| CAS-ID | 188627-80-7 |
| RxCUI | 75635 |
| ChEMBL ID | CHEMBL1174 |
| ChEBI ID | 291902 |
| PubChem CID | 448812 |
| DrugBank | DB00063 |
| UNII ID | NA8320J834 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,733 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,702 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more